Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
15.02.2024 - First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 .
HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize by HHS and Steven & Alexandra Cohen Foundation tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
WILMINGTON, Del., Dec. 11, 2023 Prelude Therapeutics Incorporated , a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in.